Endometrial cancer is the most common gynecologic malignancy in the US1,2

Nearly 60,000 new cases are expected in 20211,2

Icon: 1 in 4 Endometrial Cancer Patients
Icon: 1 in 4 Each Year

Approximately

patients experience a recurrence or are diagnosed with advanced endometrial cancer each year3,4

Icon: 1 in 4 Endometrial Cancer Patients
Icon: 1 in 4 Each Year

Approximately

patients experience a recurrence or are diagnosed with advanced endometrial cancer each year3,4

Currently, there is no generally accepted standard of care within the oncology community for the treatment of recurrent or advanced endometrial cancer that has progressed on or after platinum-based therapy.5,6

Unfortunately, most patients with recurrent or advanced endometrial cancer have a poor prognosis2,7,8

Image: JEMPERLI Doctor Discussion

Endometrial cancer has the highest rate of mismatch repair deficiency (dMMR) across tumor types9

Icon: 25-30 Percent Have dMMR Tumors

of patients with endometrial cancer have dMMR tumors7,10

Icon: 25-30 Percent Have dMMR Tumors

of patients with endometrial cancer have dMMR tumors7,10

dMMR is a biomarker that identifies a subset of patients who may respond to immunotherapy4

The MMR system repairs incorrect insertions or deletions in the repetitive units of DNA known as microsatellites. A deficient MMR system contains gene mutations or gene expression that prevent it from functioning properly. Tumors with dMMR are more likely to respond to anti–PD-1 therapy due to increased mutations that promote anti-tumor immune cell reaction and increased tumor-infiltrating lymphocytes.11-13

Determine dMMR status using immunohistochemistry (IHC)

IHC is a reliable and accurate FDA-approved test to determine dMMR status and identify patients who may benefit from immunotherapy like JEMPERLl.4,13

Consider JEMPERLI for your patients with recurrent or advanced dMMR endometrial cancer14

Icon: Lightbulb
Icon: JEMPERLI Response Rate

Learn about response with
 JEMPERLI.

Icon: JEMPERLI Trial

Explore the pivotal trial
for JEMPERLI.

Icon: JEMPERLI Mechanism of Action

Learn how JEMPERLI
activates T cells.